Recent News
Shoulder pain affects 16% of adults annually and is the third most common musculoskeletal presentation in primary care. This new review reframes the diagnostic and therapeutic approach, moving away from pathoanatomic labels (rotator cuff tendinopathy, impingement, bursitis) toward the umbrella term subacromial pain, since structural findings on imaging correlate poorly with symptoms and are common in asymptomatic people.Read Article
"Great teachers set it up, and great students find the aha."
- Seth Godin https://t.co/Fc3SPdsYCE
Links:
Dr. John Cush @RheumNow ( View Tweet)
In 2026 Abbvie granted 34 scholarships to students With Inflammatory Diseases. In the last 10 yrs, theyve granted $6 million to >350 students in the US for higher education. These awards up to $20,000 per student renewable up to 4 yrs. https://t.co/DFy5SukB6G https://t.co/9mVkrhL2lo
Dr. John Cush @RheumNow ( View Tweet)
Joint Pain Prevalence is not Declining
A current report from the national NHIS survey shows that over half of US adults diagnosed with arthritis reported moderate to severe joint pain.
Read Article
📢 “There is so much value in randomized controlled trials that directly translates to the clinic.” – Dr. Manish Jain
Listen to a discussion on SELECT-SWITCH outcomes in RA after prior TNFi failure. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/ni7IdVFobf https://t.co/1pT86TuGZ8
Dr. John Cush @RheumNow ( View Tweet)
EU Finalizes Tavneos Withdrawal - The European Commission has officially revoked the marketing authorization for Tavneos (avacopan), finalizing a process that began with regulators flagging the drug's pivotal trial data as "incorrect and misleading." The EC issued its legally https://t.co/jgysiV1hyX
Dr. John Cush @RheumNow ( View Tweet)
Doubting RS3PE (8.14.2026)
Dr. Jack Cush reviews the news and journal articles this week where RheumNow featured info on cancer, deadly viruses, AI rules, poetry and good moons rising.
https://t.co/gmcrjb5bDu https://t.co/LiLl7XcZQS
Dr. John Cush @RheumNow ( View Tweet)
Multiple chronic conditions (MCCs; AKA multimorbidity) is highly prevalent in AIRDs; complicates Rx & increases adverse outcomes & all-cause mortality. MMCs 86% in RA, 81.5% in SLE, w/ a notable patterns of cardiopulmonary and mental health disorders https://t.co/AOWCsEodXR https://t.co/NyAR0TUQkE
Dr. John Cush @RheumNow ( View Tweet)
2026 Medscape report on Nurse practitioners shows nearly half of NPs are burned out, and for 1 in 6, that exhaustion has curdled into something heavier: both burnout and depression. Worse, 63% of NPs don't believe relief is in sight https://t.co/G8N5YgOKyA
Dr. John Cush @RheumNow ( View Tweet)
SLE & Dermatomyositis rashes maybe classically red or violaceous in Whites,but different in people of color, where erythema often appears brown/violaceous, Gottron papules can be mistaken for "dry skin." This delays dx, especially in anti-MDA5+ RP-ILD, where rash may be the https://t.co/Savx5IOTcG
Dr. John Cush @RheumNow ( View Tweet)
Efgartigimod Efficacy in Idiopathic Inflammatory Myopathy
Today Argenx announced the results of their Phase 3 "ALKIVIA" study; demonstrating efficacy and safety of subcutaneous efgartigimod for Idiopathic Inflammatory Myopathy (IIM, AKA inflammatory myositis).
Read Article
Can Effective Psoriasis Therapy Prevent Psoriatic Arthritis?
A review article assesses and integrates mechanistic, imaging, and clinical evidence to examine whether effective treatment of psoriasis may modify the future risk of psoriatic arthritis (PsA).
Read Article
Rheum Survey >> What therapy do you most commonly use to treat Sjogrens disease? Answer here: https://t.co/XJEsqoSlbn
Dr. John Cush @RheumNow ( View Tweet)
Review of CAR-T 29 trials in systemic sclerosis (SSc): 27/29 target CD19 (other CD20, BCMA), 20/29 autologous. Only 2 RCTs; 1 w/ RTX comparator. Most included CREST. Schetts largest series had 6 dcSSc w/ skin/lung improvements. Need fewer & larger multicenter RCTs https://t.co/Me28HbaFhR
Dr. John Cush @RheumNow ( View Tweet)
French study of 90 RA F pts w/ 100 pregnancies (steroids 46% & biologics 39% were used). Vs 359 controls, RA had signif. more preterm birth (PTB;OR 2.08) & small for gestational age. SGA assoc w/ nulliparity (adj OR 4.38), PTB assoc w/ maternal age (aOR 1.14) & GC ≥10 mg/d (aOR https://t.co/StCJW2rsZI
Dr. John Cush @RheumNow ( View Tweet)
A Case of Sweet Syndrome
https://t.co/M4ERsHnnH7 https://t.co/88bqEemJG8
Dr. John Cush @RheumNow ( View Tweet)
ZEUS Trial: IL-6 Inhibition Fails to Cut Cardiovascular Events
The phase 3 ZEUS trial tested the IL-6 ligand inhibitor ZVK in over 6,000 patients with ASCVD, CKD, and elevated hsCRP. Although ZVK significantly lowered IL-6 and CRP levels, it did not improved outcomes (HR 0.99 https://t.co/jf2gAtvmpZ
Dr. John Cush @RheumNow ( View Tweet)
FDA & Fresenius Kabi Issues Nationwide Recall of Tyenne® (tocilizumab biosimilar) Injection 400 mg/20 mL Vials Due to Presence of Glass Particles. Applies to NDC Number 65219-594-20, Lot Number 16UI07 , Expiration date: 08/2028 . FDA warns possible ISR or VTE. https://t.co/YMRC9FO7Mu
Dr. John Cush @RheumNow ( View Tweet)
US TriNetX EHR study of of seropositive RA:  31,932 without ILD; 115 RA-ILD on antifibrotic Rx & 1885 RA-ILD not Rx w/ antifibrotics. MTX was used more in RA w/o ILD (52%) vs RA-ILD (12%) on antifibrotics. RA-ILD was assoc w/ heterogeneous antifibrotic use. https://t.co/eBJBXbnQLN
Dr. John Cush @RheumNow ( View Tweet)
3 SLE pts w/ Bx class III/IV LN had Lg proteinuria flares (4.6–13.4 g/d) despite MMF plus belimumab & were given voclosporin (+MMF) w/ rapid, sustained proteinuria reduced (≤0.7 g/day w/in 9–12 mos) & stable/improved eGFR, & GC tapering. Creat increases Rx w/ dose adjustments https://t.co/38lcD8DPgn
Dr. John Cush @RheumNow ( View Tweet)
From the Blog
At first, it seemed similar to many other such sessions – a circle of folding chairs, a group of colleagues whose visages exuded understanding and acceptance – but this was special. I started the meeting…. “Hi, my name is Artie.”
Read Post
Podcasts
Doubting RS3PE (8.14.2026)-
Mentshlichkeit (8.7.2026)
A JAKi After TNFi Failure in RA: SELECT-SWITCH at Week 12
TU: Systemic Burden of Gout Part 2 (24 plus)
Therapeutic Updates
Make Rheum for Rads: Autoimmune ILD Diagnosis, Monitoring, and the Patient Experience
Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
Drs. Elizabeth Volkmann and Robert Suh explore the roles rheumatologists and radiologists play in diagnosing and monitoring autoimmune ILD and hear from a patient about her experience.
Read Post
Fundamentals of CAR T Cell Therapy and Its Investigational Use in Autoimmune Diseases
Sponsored By Bristol Myers Squibb
Learn more about the fundamentals of CAR T-cell therapy and its investigational use in autoimmune disease
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
